J&J’s Swift $14.6B Acquisition of Intra-Cellular Therapies: A CEO-Driven Deal
Johnson & Johnson agreed to acquire Intra-Cellular Therapies for $14.6 billion, or $132 per share in cash15.
The deal was facilitated by J&J CEO Joaquin Duato and took just one month from initial offer to agreement4.
This acquisition is the largest biopharma M&A transaction since 20231.
The deal centers around Intra-Cellular's drug CAPLYTA (lumateperone), approved for schizophrenia and bipolar depression15.
J&J expects CAPLYTA to generate more than $5 billion in peak year sales1.
The acquisition strengthens J&J's neuroscience portfolio and aligns with its commitment to addressing neuropsychiatric and neurodegenerative disorders68.
Intra-Cellular's pipeline includes promising compounds like ITI-1284, currently in Phase II trials for various neurological conditions68.
The deal is expected to close later in 2025, subject to regulatory approvals and other customary conditions56.
This acquisition marks a significant investment in the neuroscience field, following recent deals by other pharmaceutical companies in this area58.
The transaction demonstrates J&J's strategy to pursue larger acquisitions when they align with the company's growth objectives and areas of expertise1.
Sources:
1. https://www.genengnews.com/gen-edge/jj-to-acquire-intra-cellular-for-14-6b/
4. https://www.bmpharmaceuticals.com/jj-ceo-broke-a-stalemate-and-facilitated-the-14-6b-intra-cellular-buyout-in-a-whirlwind-month-filing/
5. https://www.biopharmadive.com/news/johnson-johnson-intra-cellular-acquire-deal-schizophrenia-caplyta/737126/
6. https://www.globenewswire.com/news-release/2025/01/13/3008254/30597/en/Johnson-Johnson-Strengthens-Neuroscience-Leadership-with-Acquisition-of-Intra-Cellular-Therapies-Inc.html
8. https://www.biospace.com/business/johnson-johnson-makes-major-neuro-play-with-14-6b-intra-cellular-buyout